Minulet - Dragees (Ethinylestradiol, Gestodene)

Minulet, a combined oral contraceptive, is indicated for hormonal contraception to prevent pregnancy.

• Contraception (prevention of pregnancy): provides reliable birth control for women of child‑bearing age.
• Menstrual cycle regulation: helps achieve more predictable bleeding patterns and reduces menstrual discomfort.
• Acne improvement: may lessen acne severity by modulating androgen activity in the skin.

• Ethinylestradiol and gestodene act synergistically on the hypothalamic‑pituitary‑ovarian axis. Ethinylestradiol, a synthetic estrogen, suppresses the mid‑cycle surge of luteinising hormone (LH) and follicle‑stimulating hormone (FSH), while gestodene, a progestogen, reinforces this inhibition and stabilises the endometrium. Together they prevent ovulation, thicken cervical mucus and alter the endometrial lining, reducing the chance of fertilisation and implantation. The combined hormonal effect also suppresses endogenous gonadotropin release, maintaining contraceptive efficacy throughout the dosing cycle.

Like all hormonal contraceptives, Minulet may be associated with a range of adverse reactions.

Common Side Effects

• Nausea: mild stomach upset.
• Headache: tension‑type pain.
• Breast tenderness: swelling or discomfort.
• Spotting or breakthrough bleeding: irregular light bleeding.

Serious or Rare Side Effects

• Venous thromboembolism: deep vein thrombosis or pulmonary embolism.
• Arterial thrombosis: stroke or heart attack.
• Severe allergic reaction: rash, swelling, or anaphylaxis.

Before prescribing Minulet, healthcare professionals should consider several precautionary measures to ensure safe use.

• Contraindications: avoid in women with a history of thromboembolic disorders, estrogen‑dependent tumors, or uncontrolled hypertension.
• Smoking: do not use in patients over 35 who smoke heavily, as cardiovascular risk increases.
• Liver disease: use with caution in patients with hepatic impairment.
• Medication history: review current use of enzyme‑inducing drugs that may reduce contraceptive efficacy.
• Pregnancy testing: confirm non‑pregnant status before initiating therapy.
• Store at ambient temperature: keep below 25 °C, in the original packaging, protected from moisture and light.

Minulet can interact with other medicines, altering its effectiveness or increasing adverse effects.

Major Interactions (Avoid)

• Antiepileptic enzyme inducers (e.g., carbamazepine, phenytoin, rifampicin): markedly reduce hormone levels, risking contraceptive failure.
• Certain antibiotics (e.g., griseofulvin): may decrease contraceptive efficacy.
• Antiretroviral protease inhibitors (e.g., ritonavir): can increase hormone concentrations, raising side‑effect risk.

Moderate Interactions (Monitor Closely)

• St. John’s wort: may lower plasma hormone levels.
• Antifungal azoles (e.g., ketoconazole): may increase hormone levels.
• Diuretics and antihypertensives: may affect fluid balance and blood pressure.